Drugs / EB612 (EBP05)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03516773 | Jun → Dec 2018 | hypoparathyroidism | Entera Bio Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB612 (EBP05) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03516773 ↗ |
| Route | Oral | “EB612 (EBP05) 2.25 mg orally (PO) four times a day (QID)” NCT03516773 ↗ |